Rational design of polysorbate 80 stabilized human serum albumin nanoparticles tailored for high drug loading and entrapment of irinotecan

Taneja, Neetika; Singh, Kamalinder K.

doi:10.1016/j.ijpharm.2017.11.024

Cited by 34 publications

(8 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fluorescence quenching is a common technique used to study the interaction between a protein and a drug (the quencher) [30]. Although no SN-38 crystal was observed visually, we conducted a fluorescence quenching experiment to study the interaction between albumin and SN-38.…”

Section: Discussionmentioning

confidence: 99%

High Potency of SN-38-Loaded Bovine Serum Albumin Nanoparticles Against Triple-Negative Breast Cancer

et al. 2019

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with a worse prognosis than other types. There are currently no specific approved treatments for TNBC. Albumin is a promising biomimetic material that may be fabricated into nanoparticles to possibly exert passive effects on targeted tumors. Irinotecan has been extensively used in clinical settings, although a high dosage is required due to its low efficiency of conversion into the active metabolite SN-38, also known as 7-ethyl-10-hydroxy-camptothecin. The aim of this work was to optimize SN-38-loaded bovine serum albumin nanoparticles (sBSANPs) and evaluate their potency against TNBC. The sBSANPs were characterized by a small size of about 134–264 nm, a negative charge of −37 to −40 mV, an entrapment efficiency of 59–71%, and a particle yield of 65–86%. The cytotoxicity assays using sBSANPs showed a higher potency specifically against both MDA-MB-468 and MDA-MB-231 cells (ER−, PR−, HER2−) compared to MCF-7 (ER+, PR+, HER2−), and exhibited an extremely low IC50 at the nanomolar levels (2.01–6.82 nM). The release profiles indicated that SN-38 presented an initial burst release within 12 h, and sBSANPs had a slow release pattern. Flow cytometry results showed that the fluorescence intensity of sBSANPs was significantly higher than that of the control group. The confocal images also confirmed that sBSANPs were taken up by MDA-MB-468 cells. Moreover, we found that a larger BSANP size resulted in an increased hemolytic effect. In vivo animal studies demonstrated that loading of SN-38 into bovine serum albumin nanoparticles could minimize the initial concentration without extending the elimination half-life, but significantly minimized the Cmax (p < 0.001) as compared with irinotecan treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

High Potency of SN-38-Loaded Bovine Serum Albumin Nanoparticles Against Triple-Negative Breast Cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Drugs that use human serum albumin as a carrier can enhance the dissolution rate and saturation solubility of drugs by intravenous injection. Cumulative data show that when the poorly hydrophilic drug binds to human serum albumin, the bioavailability of the drug can be increased (Kumar et al, 2013;Taneja & Singh, 2017).…”

Section: Introductionmentioning

confidence: 99%

Resveratrol loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles for tail vein injection II: pharmacokinetics, tissue distribution and bioavailability

Chen

Deng

et al. 2019

Drug Delivery

View full text Add to dashboard Cite

There are many kinds of biological activities of resveratrol itself, but its clinical application is limited by its poor solubility in water and low bioavailability. Therefore, we have prepared glycyrrhizic acid-conjugated human serum albumin nanoparticles wrapping resveratrol nanoparticles (GL-HSA-RESNPs). The purpose of this study was to investigate the bioavailability, pharmacokinetics and tissue distribution of resveratrol in rats after single-dose tail vein injection administration of GL-HSA-RESNPs. A sensitive and reliable high performance liquid chromatography (HPLC) method was established to verify the content of resveratrol in rat plasma and organs. The C max value after GL-HSA-RESNPs administration was significantly higher than that of resveratrol suspension (933 ± 76.64 ng/mL vs. 618 ± 42.54 ng/mL, p < .01). The T max value obtained after GL-HSA-RESNPs administration was significantly shorter than that after resveratrol suspension administration (0.17 ± 0.01 h vs. 0.25 ± 0.01 h, p < .001). The bioavailability of GL-HSA-RESNPs was 4.25 times higher than that of the pure resveratrol. The concentration of resveratrol in the main organs of rats treated with the GL-HSA-RESNPs was higher than that in rats treated with the pure resveratrol. Rats treated with GL-HSA-RESNPs had the highest concentration of resveratrol in their liver. It is indicated that GL-HSA-RESNPs is a promising liver-targeted delivery system that improves the in vivo bioavailability of resveratrol.

show abstract

“…In this study, albumin nanoparticles loaded with a combination of CRB and DEC were successfully prepared by using a modified desolvation method, which is an accepted method for entrapping hydrophilic drugs into albumin nanoparticles [26, 27]. The physicochemical properties of CRB‐ and DEC‐loaded albumin nanoparticles are summarized in Table 4 and the related chromatogram is displayed in Fig.…”

Section: Resultsmentioning

confidence: 99%

A novel stability‐indicating analytical method development for simultaneous determination of carboplatin and decitabine from nanoparticles

Esim

Gümüştaş

Hasçicek

et al. 2020

J of Separation Science

View full text Add to dashboard Cite

Drug resistance is one of the main problems of cancer treatment. For this reason, combination therapy is commonly used for years. The combination of a chemotherapeutic, carboplatin, and the epigenetic drug decitabine is a new approach to modulate drug resistance. Nanoparticulate systems can overcome the drawbacks associated with the drug combinations. An analytical method that can detect and quantify carboplatin and decitabine which is encapsulated into the nanoparticles is necessary for nanoparticle development. In the literature, there is no analytical method in which carboplatin and decitabine are determined simultaneously. The primary purpose of this study is to develop and validate a novel, and stability‐indicating high‐performance liquid chromatography method for simultaneous determination of carboplatin and decitabine in pharmaceutical preparations in addition to developing the first nanoformulation for this drug combination. Therefore, various experimental parameters were optimized. The chromatographic separation was achieved using an XSelect® CSH C18 (250 × 4.6 mm I.D., 5 µm) column and a mobile phase consisting of methanol:water (containing 0.1% phosphoric acid) (3:97, v/v). The mobile phase pH was adjusted to 7.0 with 5 M NaOH. The developed method was successfully applied for the simultaneous determination and quantification of carboplatin and decitabine co‐encapsulated in nanoparticles and released into in vitro dissolution medium.

show abstract

Rational design of polysorbate 80 stabilized human serum albumin nanoparticles tailored for high drug loading and entrapment of irinotecan

Cited by 34 publications

References 84 publications

High Potency of SN-38-Loaded Bovine Serum Albumin Nanoparticles Against Triple-Negative Breast Cancer

High Potency of SN-38-Loaded Bovine Serum Albumin Nanoparticles Against Triple-Negative Breast Cancer

Resveratrol loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles for tail vein injection II: pharmacokinetics, tissue distribution and bioavailability

A novel stability‐indicating analytical method development for simultaneous determination of carboplatin and decitabine from nanoparticles

Contact Info

Product

Resources

About